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ABSTRACT
Background: The PTPN22 gene has been widely
confirmed as a susceptibility gene for rheumatoid arthritis
(RA) in populations of Northern European descent. The
aim of the current study was to explore the role of
variants spanning the PTPN22 gene in determining
susceptibility to and outcome of inflammatory polyarthritis
(IP).
Patients and methods: Single nucleotide polymorphism
(SNP) variants spanning the gene were genotyped using
the Sequenom MassArray platform and tested, firstly for
their association with susceptibility to IP. Genotype
frequencies were compared between new onset IP cases
(n=843) and population controls (n=471). Secondly, a
within-cohort analysis was performed testing each variant
for association with a number of clinical outcome
measures reflecting disease severity including radiological
erosions, physical function, measured using the Health
Assessment Questionnaire (HAQ) score, and disease
activity at defined time-points following disease pre-
sentation.
Results: A significant association between carriage of
the PTPN22*1858T allele and IP (odds ratio (OR)=1.4
(95% CI 1.1–1.9), p=0.02) was observed. The strength
of the effect was similar in the RA subgroup (OR=1.4
(95% CI 1.0–1.9), p=0.05). No association between IP
susceptibility and any of the other SNPs was detected.
No association was detected for any of the SNPs tested,
including the PTPN22*C1858T polymorphism, for either
erosive status, Larsen score by 5 years or other markers
of clinical outcome.
Conclusion: The PTPN22*C1858T polymorphism is
associated with susceptibility to IP, but we have found no
evidence for association of this or other variants spanning
the gene with clinical outcome measures.
A considerable genetic contribution to rheumatoid
arthritis (RA) is demonstrated by both twin and
family studies.
1 The strongest association to date
has been found with the HLA-DRB1 gene and, in
particular, with alleles that code for a consensus
amino acid sequence within the third hypervariable
region of the DRB1 chain (the shared-epitope).
More recently, progress has been made in identify-
ing other RA susceptibility genes (reviewed in
Orozco et al).
2 The most convincing association has
been demonstrated with a functional single
nucleotide polymorphism (SNP) mapping to the
lymphoid tyrosine phosphatase, PTPN22, gene
(PTPN22*C1858T).
3 This finding has been widely
and consistently replicated in populations of
Northern European descent.
4
The PTPN22 gene maps to chromosome 1p13
and codes for a tyrosine phosphatase that is
involved in immune regulation as a negative
regulator of T cell activity. The polymorphism
results in the substitution of the wild-type,
arginine, with a variant, tryptophan, amino acid
at codon 620 (R620W). Recent work suggests that
the polymorphism may lead to a ‘‘gain-of-func-
tion’’ as the protein has been shown to be changed
into a more active tyrosine phosphatase in the
presence of the tryptophan variant.
5 It is hypothe-
sised that reduced T-cell signalling may occur as a
result and, in turn, this may enable auto-reactive T
cells to escape deletion during thymic selection and
thus persist in the circulation to become activated
at a later stage. Although the primary association is
with the PTPN22*C1858T polymorphism, evidence
for independent association of three other SNPs
mapping within the gene with susceptibility to RA
has since been reported but this finding has not
been replicated in two subsequent studies.
6–8
In the clinical setting, the greatest utility for
genetic markers would be if they led to the
identification of a marker that could predict, at
the earliest stages of inflammatory polyarthritis
(IP), which patients will proceed to develop more
severe disease. This could help to identify a
subgroup of patients that could be targeted for
aggressive therapy, while sparing those least likely
to develop severe disease from the potential side
effects associated with such drug therapy. While
both the shared epitope and the PTPN22*C1858T
allele are certainly associated with RA, the ques-
tion of whether these associations are primarily
with susceptibility or severity has proved difficult
to determine because many previous studies have
investigated cross-sectional series of hospital-based
cases that often represent the severe end of the
spectrum of disease. Ideally, such studies should be
performed in inception cohorts of patients fol-
lowed prospectively. In an unselected series of
patients presenting to primary care with early IP
and followed prospectively as part of the Norfolk
Arthritis Register (NOAR), we have previously
shown that the shared epitope is more strongly
associated with severity markers such as radiologi-
cal erosions than with susceptibility.
9
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stronger associations in patients with a family history of disease
and in patients with a younger age at onset suggesting that this
polymorphism, too, may be associated more with severity than
susceptibility.
31 0However, these studies were cross-sectional in
nature and subject to the methodological biases outlined. Only
one study has examined an inception cohort followed prospec-
tively.
11 They reported no association with remission or rates of
RA joint destruction but an association between PTPN22*1858T
risk allele and autoantibody production was noted.
We have used the opportunity afforded by the NOAR cohort
to address the question of firstly, whether other variants
spanning the PTPN22 gene are associated with susceptibility to
IP and, secondly, whether any is associated with outcome of
disease.
MATERIALS AND METHODS
Study design
SNP variants spanning the PTPN22 gene were tested firstly for
their association with susceptibility to IP by comparing
genotype and allele frequencies between new onset IP cases
with population controls. Secondly, a within-cohort analysis
was performed testing each variant for association with a
number of clinical outcome measures reflecting disease severity
including presence of radiological erosions, physical function as
measured using the Health Assessment Questionnaire (HAQ)
score and disease activity at defined time-points following
disease presentation.
12
Study population
Cases were recruited from NOAR, a primary care-based cohort
of subjects with new onset IP.
13 In brief, NOAR aims to recruit
all new adult attendees at primary care with IP, defined as
swelling of two or more joints, lasting .4 weeks, after
exclusion of diagnoses other than undifferentiated IP, post-viral
IP, RA or psoriatic arthritis. Subjects are assessed by trained
metrologists, within 2 weeks of referral, using a standardised
approach. Data gathered included joint counts for swelling and
tenderness. Blood was taken for serum analysis (rheumatoid
factor (RF), C-reactive protein (CRP) and anti-cyclic citrinulated
peptide (CCP) testing) and DNA extraction. Subjects were
followed up annually thereafter.
13 The 1987 criteria for RA were
applied at every visit and subjects classified as having RA if they
had cumulatively satisfied the criteria by that time point.
14 At
baseline and annually thereafter the subjects completed the
eight-domain HAQ. Radiographs of the hands and feet were
obtained at 1 and/or 5 years. The criteria for requesting
radiographs and the scoring process have been published
previously.
15 The radiographs were read by two readers (with
arbitration by a third where necessary) using the Larsen
method.
16 For the purposes of this study, consecutive patients
recruited between 1990 and 1994 who had a DNA sample
available were selected.
Data for unmatched control individuals recruited from
Norfolk general practitioners’ records or from blood donors
were available and have been reported previously.
7 All subjects
were of UK Caucasoid origin. The study was conducted with
ethical approval (LREC 2003-075, MREC 99/8/84) and all
patients gave their informed consent.
Serological tests
Baseline serum samples were assayed for RF was using a latex
method and a titre of >1:40 was regarded as positive. CRP was
measured using nephelometry (http://www.bmglabtech.com/
templates/applications). Anti-CCP testing was performed using
the Axis-ShieldH DIASTAT
TM kit according to manufacturer’s
instructions and a result of .5 U/ml was regarded as positive
(Axis-Shield, Dundee, UK).
Genotyping
Thirteen SNPs spanning the PTPN22 gene were selected for
investigation. These included the PTPN22*C1858T polymorph-
ism, seven tagging SNPs and two of three potentially functional
polymorphisms identified by Carlton et al.
6 The third SNP,
rs3789604 (SNP 37), was not selected for genotyping because of
the strong LD exhibited between this and another of the
selected SNPs, rs3811021 (SNP 36). Genotyping was undertaken
using the SequenomH iPLEX platform
TM, according to the
manufacturer’s instructions
17 (http://www.sequenom.com).
Samples were plated onto 26384-well plates. Duplicate samples
and negative controls were included to check genotyping
quality. For the PTPN22*C1858T (rs2476601, R620W) SNP,
additional samples from the cohort had been genotyped in-
house previously and that data was included in the current
analysis. Only SNPs that were successfully genotyped in .90%
samples were included in the analysis.
Statistical analysis
Genotype and allele carriage frequencies for each SNP were
compared between cases and controls using the x
2 test for trend
and odds ratios (OR) with 95% confidence interval (CI),
respectively. Given the linkage disequilibrium known to exist
across the gene, logistic regression was undertaken conditioned
on the effect of the associated SNP, rs2476601 (R620W).
Estimated haplotypes were constructed in Haploview v3.2
18
and frequencies compared between cases and controls.
For the within-cohort analysis of association with disease
severity, a number of measures were assessed reflecting disease
activity (CRP at baseline, swollen joint count at baseline and at
5 years following presentation), severity (presence of erosions
by 1 and 5 years, Larsen score by 1 and 5 years, presence of anti-
CCP antibodies and RF at baseline) and disability (HAQ score).
Categorical data (erosions by 1 and 5 years, anti-CCP and RF)
were analysed using the x
2 test while continuous variables were
analysed using the Mann–Whitney U test. All analyses were
performed in the cohort as a whole and in the subset of patients
fulfilling American College of Rheumatology (ACR) criteria for
RA by 5 years using STATAH (StataCorp LP, College Station,
Texas, USA).
For the PTPN22*C1858T SNP, there was a clear a priori
hypothesis for testing for association with IP and so no
correction was made for multiple testing. However, for the
other SNPs tested, the prior probability of detecting association
was small and a Bonferroni correction of 12 was applied to
correct for number of SNPs tested.
RESULTS
Subjects
In total, 1098 patients were recruited to NOAR between 1990
and 1994 and a DNA sample was available from 843 of them.
However, for the majority of SNPs, only 750 samples were
tested. Clinical characteristics of the cases are detailed in table 1
and are similar to those reported previously from the NOAR
cohort.
14 The median age at onset of IP was 53 (interquartile
range (IQR) 40–65), 539 (64%) were female and 79.4% had been
referred to hospital (secondary care) following onset of their
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were female and the median age at the time of sample donation
was 66 (interquartile range (IQR) 42–75). This data has been
published previously.
7 All cases and controls were of UK white
Caucasian ethnicity.
Genotyping
Genotype frequencies for one SNP (ss38346943) deviated from
Hardy–Weinberg equilibrium (p,0.01) in the control popula-
tion and it was excluded from the susceptibility analysis. One
variant (ss38346944) was not tested in the control samples, and
hence investigation of this marker was restricted to the analysis
of clinical outcome.
Association with IP susceptibility
Genotype distributions differed significantly at the
PTPN22*C1858T polymorphism between IP cases and controls
(p=0.02) (table 2). In addition, there was a significant
association between carriage of the PTPN22*1858T allele and
IP (odds ratio (OR)=1.42 (95% CI 1.06–1.90), p=0.02). The
strength of the effect was similar in the RA subgroup
(OR=1.38 (95% CI 1.01–1.89), p=0.04) and the IP cohort as
a whole. No association between IP and any of the other SNPs
was detected either when analysed by genotype (table 2) or by
allele. Stratifying the cohort for the fulfilment of ACR criteria
for RA by 5 years did not alter these conclusions (data not
shown).
When the analysis was performed using logistic regression to
adjust for the genotype at the rs2476601 (R620W) SNP, another
SNP showed evidence for association with susceptibility:
rs1217388 (SNP 32; uncorrected p=0.003). However, the only
haplotype occurring significantly more frequently in cases than
controls was the haplotype carrying the risk allele at rs2476601
(R620W) (12.4% cases, 9.3% controls, p=0.03). When chromo-
somes carrying the risk allele were excluded, no evidence for
association of the remaining haplotypes with RA was found.
Furthermore, haplotypes carrying the risk allele at rs1217388
(SNP 32), showed no difference in frequency between cases and
controls.
Association with clinical outcome measures
No association was detected for any of the SNPs tested,
including the PTPN22*C1858T polymorphism, with either
erosive status or Larsen score by 5 years (table 3). A trend for
association of the Larsen score by 5 years was noted with SNP
rs1217413 (SNP35) but this was not significant when a
Bonferroni correction was applied. Furthermore, no association
with Larsen score at 1 year or with any other clinical outcome
measure was detected (data not shown). None of the other
SNPs tested demonstrated statistical evidence for association
either in the IP cohort as a whole (table 3) or in the subgroup
satisfying ACR criteria for RA by 5 years (data not shown). No
association was detected with other markers of outcome tested
such as HAQ score at presentation or by 5 years, swollen and
tender joint counts at presentation or by 5 years or CRP at
baseline for any of the SNPs spanning the gene (data not
shown).
Association with autoantibody status
There was a significant association between the variant allele of
the PTPN22*C1858T (rs2476601) SNP and baseline anti-CCP
status in the RA subgroup (p=0.003) (table 4).
DISCUSSION
In this unselected primary care-based inception cohort of
patients, we have confirmed the association between the
PTPN22*C1858T polymorphism and susceptibility to IP but
found no association with severity using a number of clinical
outcome markers. We have also failed to find any association
between disease susceptibility or severity and other polymorph-
isms spanning the gene.
The association of the PTPN22*1858T variant with suscept-
ibility to RA has been widely replicated in white European
populations.
4 This polymorphism has also been found to be
associated with susceptibility in two other inception cohorts
with early disease (OR 1.3 and 1.5).
11 19 The effect size detected
in the current study (OR=1.4) is in keeping with those reports
and suggests that the variant confers a modest increase in risk.
One explanation for the lower effect sizes detected in studies
of early disease compared to established series of RA patients
may be that the PTPN22*C1858T variant is associated with
disease severity as well as susceptibility. An inception cohort,
such as NOAR, followed prospectively is required to dissect
these issues. The NOAR cohort is representative of patients
with new-onset IP seen in general practice. A total of 79.4%
were referred to hospital within the 5 years of follow-up, while
75% satisfied ACR classification criteria for RA by 5 years. The
choice of relevant outcome measures is the subject of some
debate. The development of radiological erosions is generally
regarded as a reliable and validated measure of severity but, the
earlier use of disease-modifying (DMARD) therapy may mean
that erosions are of less clinical relevance. Furthermore, the level
of disability experienced by patients is of far greater impor-
tance to them than x ray appearances. Hence, a measure of
physical function such as the HAQ score may provide a more
relevant outcome measure. We have tested multiple measures of
disease outcome but, despite this, we have found no asso-
ciation of the PTPN22*C1858T polymorphism with disease
severity. One possibility is that the PTPN22*C1858T poly-
morphism is associated with outcome but this was masked
by the effect of treatment. This could occur if patients carry-
ing the variant allele were more likely to receive DMARD
treatment. However, this was not found to be the case (OR
receiving DMARDs compared with not receiving DMARDs if
carrying the PTPN221858*T variant = 1.36 (95% CI 0.84–2.24),
p=0.19).
Table 1 Clinical data for subjects with inflammatory polyarthritis (IP)
Characteristic Cases (n=843)
RF positive, n (%):
Baseline 202/773 (26%)
Erosive, n (%):
By 1 year 159/476 (33%)
By 5 years 202/487 (41%)
Anti-CCP positive at baseline, n (%) 181/682 (27%)
ACR criteria fulfilled by 5 years, n (%) 519/769 (67%)
Median swollen joint count (IQR):
At baseline 4 (1–10)
At 5 years 0 (0–1)
Median HAQ score (IQR):
At baseline 0.75 (0.25–1.38)
At 5 years 0.25 (0.25–1.5)
Median CRP at baseline (IQR) 5 (0–15)
The denominator details the number of subjects where information was available.
ACR, American College of Rheumatology; CCP, cyclic citrinulated peptide; HAQ, Health
Assessment Questionnaire; IQR, interquartile range; RF, rheumatoid factor.
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(SNP 27), rs3811021 (SNP 36) and rs3789604 (SNP 37)) were
associated with susceptibility to RA independently of the
PTPN22*C1858T polymorphism.
6 Their association with IP has
not previously been determined. We did not test rs3789604
(SNP 37) in the current study but another SNP (rs3811021 (SNP
36)), which shows strong correlation with rs3789604, was
examined. However, we found no association with suscept-
ibility, either in IP as a whole or in the subgroup with RA, for
any of the variants tested other than the PTPN22*C1858T
polymorphism. Similarly, no evidence for association with
severity measures was found, although it should be noted that
the low minor allele frequencies for some of the SNP markers
(particularly for ss38346944 (SNP 23), ss38346943 (SNP 28) and
ss38346942 (SNP 34)) meant that power to test such association
was limited.
Although the PTPN22*C1858T polymorphism was not
associated with clinical markers of severity, in the subgroup of
patients who fulfilled the ACR classification criteria for RA by 5
years, a statistically significant association with the presence of
anti-CCP antibodies at baseline was detected, in keeping with
previous reports.
11 20 The presence of anti-CCP antibodies is
strongly associated with adverse outcome. For example, the
odds ratio for the presence of erosions by 2 years in patients
who are anti-CCP antibody positive at baseline has been
reported as 5.4 (95% CI 1.7–17.0).
21 Hence, although the
PTPN22*1858T variant is associated with the presence of anti-
CCP antibody, it is the autoantibody that appears to determine
severity. The findings are in keeping with the hypothesis that
the PTPN22*1858T allele, like HLA-DRB1 shared epitope alleles,
may create a permissive environment for the production of
these antibodies.
22
In summary, carriage of the PTPN22*1858T variant allele is
associated with susceptibility both to IP and RA, conferring a
modest increase in risk of approximately 40%. The association
appears to be solely accounted for by this SNP. Although the
PTPN22*1858T variant allele was associated with the presence
of anti-CCP autoantibodies, neither this nor other polymorph-
isms spanning the gene were found to be clinically useful
predictors of adverse outcome.
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Table 2 Genotype data for single nucleotide polymorphisms (SNPs) spanning the PTPN22 gene in patients with inflammatory polyarthritis (IP) and
controls
SNP (no. from Carlton study)
Cases Controls
p Value (uncorrected) Sample size 1/1 n (%) 1/2 n (%) 2/2 n (%) Sample size 1/1 n (%) 1/2 n (%) 2/2 n (%)
rs1217414 (SNP 1) 736 386 (52.4) 305 (41.4) 45 (6.1) 398 221 (55.6) 161 (40.4) 16 (4.0) 0.16
rs2488458 (SNP 2) 746 425 (57.0) 278 (37.3) 43 (5.8) 387 209 (54.0) 156 (40.3) 22 (5.7) 0.45
rs12760457 (SNP 18) 731 355 (48.6) 320 (43.8) 56 (7.7) 390 182 (46.7) 179 (45.9) 29 (7.4) 0.67
rs11102685 (SNP 20) 742 614 (82.7) 119 (16.0) 9 (1.2) 403 340 (84.4) 61 (15.1) 2 (0.5) 0.35
rs12730735(SNP 21) 736 360 (48.9) 322 (43.8) 54 (7.3) 357 169 (47.3) 160 (44.8) 28 (7.9) 0.61
rs2476601(SNP22)
(PTPN22*C1858T)
832 641 (77.0) 178 (21.4) 13 (1.6) 412 342 (83.0) 66 (16.0) 4 (1.0) 0.02
rs1310182 (SNP 27) 683 227 (33.2) 323 (47.3) 133 (19.5) 351 101 (28.8) 175 (49.9) 75 (21.3) 0.17
rs1217388 (SNP 32) 736 416 (56.5) 275 (37.4) 45 (6.1) 400 208 (52.0) 168 (42.0) 24 (6.0) 0.24
ss38346942 (SNP 34) 720 694 (96.4) 26 (3.6) 0 (0.0) 386 375 (97.2) 11 (2.8) 0 (0.0) 0.50
rs1217413 (SNP 35) 732 433 (59.2) 259 (35.4) 40 (5.5) 383 240 (62.7) 126 (32.9) 17 (4.4) 0.22
rs3811021 (SNP 36) 699 446 (63.8) 215 (30.8) 38 (5.4) 386 247 (64.0) 129 (33.4) 10 (2.6) 0.41
1, major (wild-type) allele; 2, minor (variant) allele.
Table 3 Allelic association of single nucleotide polymorphisms (SNPs) spanning PTPN22 gene with erosive status and Larsen score by 5 years
SNP (no. from Carlton study)
Erosive status by 5 years/minor allele frequency, n (%) Median Larsen* score at 5 years, by allele{ (IQR)
Erosive, n (%)
Non-erosive, n
(%) OR (95% CI) p Value Allele 1 Allele 2 p Value{
Rs1217414 (SNP 1) 86 (26.9) 114 (24.4) 1.14 (0.8–1.6) 0.43 5 (0–20) 6 (0–29) 0.72
rs2488458 (SNP 2) 73 (22.3) 119 (24.9) 0.86 (0.6–1.2) 0.39 5 (0–21) 4 (0–20) 0.05
rs12760457 (SNP 18) 98 (30.4) 150 (31.8) 0.94 (0.7–1.3) 0.69 4 (0–21) 5 (0–19) 0.52
rs11102685 (SNP 20) 34 (10.3) 40 (8.4) 1.30 (0.8–2.0) 0.34 5 (0–20) 9 (0–30) 0.84
rs12730735 (SNP 21) 95 (29.5) 147 (31.1) 0.92 (0.7–1.3) 0.62 4 (0–21) 5 (0–19) 0.63
rs2476601 (SNP 22) (PTPN22*C1858T) 45 (11.1) 65 (11.6) 0.96 (0.6–1.4) 0.84 5 (0–20) 5 (0–17) 0.74
ss38346944 (SNP 23) 9 (3.0) 8 (1.9) 1.62 (0.6–4.1) 0.32 5 (0–20) 10 (2–30) 0.32
rs1310182 (SNP 27) 133 (43.2) 180 (44.6) 0.95 (0.7–1.3) 0.72 6 (0–23.5) 5 (0–22) 0.93
ss38346943 (SNP 28) 15 (4.7) 19 (4.2) 1.13 (0.6–2.2) 0.72 5 (0–21) 6 (2–20) 0.26
rs1217388 (SNP 32) 72 (22.2) 118 (24.8) 0.87 (0.6–1.2) 0.40 5 (0–21) 4 (0–18) 0.11
ss38346942 (SNP 34) 3 (1.0) 10 (2.1) 0.43 (0.1–1.5) 0.19 5 (0–20) 0 (0–7) 0.06
rs1217413 (SNP 35) 64 (19.6) 114 (24.5) 0.75 (0.5–1.0) 0.11 5 (0–22) 3 (0–17) 0.007
rs3811021 (SNP 36) 68 (22.2) 99 (21.9) 1.0 (0.7–1.4) 0.92 5 (0–20) 3 (0–20) 0.49
Uncorrected p values are presented. Allele 1, major (wild-type) allele; allele 2, minor (variant) allele.
*Larsen score in all subjects with information available. When the analysis was restricted to patients who were erosive, the conclusions were not altered; {x
2; {logistic regression
by genotype.
IQR, interquartile range; OR, odds ratio.
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Autoantibody at baseline
IP Cohort RA subset
PTPN22*CC, n (%) PTPN22*CT or PTPN22*TT, n (%) PTPN22*CC, n (%) PTPN22*CT or PTPN22*TT, n (%)
RF present 185 (74.0) 65 (26.0) 155 (74.5) 53 (25.5)
RF absent 442 (78.2) 123 (21.8) 231 (79.4) 60 (20.6)
Comparison: p value 0.19 0.20
Anti-CCP present 109 (68.5) 50 (31.5) 102 (69.4) 45 (30.6)
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Comparison: p value 0.09 0.003
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